WO2013151594A3 - Catulin as a marker and therapy target for highly motile squamous cell carcinoma metastatic cells and normal wound healing - Google Patents

Catulin as a marker and therapy target for highly motile squamous cell carcinoma metastatic cells and normal wound healing Download PDF

Info

Publication number
WO2013151594A3
WO2013151594A3 PCT/US2013/000080 US2013000080W WO2013151594A3 WO 2013151594 A3 WO2013151594 A3 WO 2013151594A3 US 2013000080 W US2013000080 W US 2013000080W WO 2013151594 A3 WO2013151594 A3 WO 2013151594A3
Authority
WO
WIPO (PCT)
Prior art keywords
catulin
amount
sample
cell carcinoma
squamous cell
Prior art date
Application number
PCT/US2013/000080
Other languages
French (fr)
Other versions
WO2013151594A2 (en
Inventor
Agnieszka KOBIELAK
Christine CAO
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Publication of WO2013151594A2 publication Critical patent/WO2013151594A2/en
Publication of WO2013151594A3 publication Critical patent/WO2013151594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are methods of detecting metastatic cancer in a subject. The method may include measuring an amount of catulin in a sample from the subject; and comparing the amount of catulin in the sample to an amount of catulin in a control, wherein an increased level of catulin in the sample relative to the amount in the control indicates metastatic cancer in the sample. Further provided are methods of treating metastatic cancer. The method may include administering to a subject an effective amount of a therapeutic composition adapted to reduce the amount or the activity of catulin. The cancer may comprise squamous cell carcinoma. The cancer may comprise breast cancer. The amount of catulin in the sample may be measured by catulin antigen-antibody binding.
PCT/US2013/000080 2012-04-04 2013-03-15 Catulin as a marker and therapy target for highly motile squamous cell carcinoma metastatic cells and normal wound healing WO2013151594A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261620249P 2012-04-04 2012-04-04
US61/620,249 2012-04-04
US201261650464P 2012-05-22 2012-05-22
US61/650,464 2012-05-22

Publications (2)

Publication Number Publication Date
WO2013151594A2 WO2013151594A2 (en) 2013-10-10
WO2013151594A3 true WO2013151594A3 (en) 2015-06-18

Family

ID=49301146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/000080 WO2013151594A2 (en) 2012-04-04 2013-03-15 Catulin as a marker and therapy target for highly motile squamous cell carcinoma metastatic cells and normal wound healing

Country Status (1)

Country Link
WO (1) WO2013151594A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767720B1 (en) * 1999-12-23 2004-07-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw CDNAs encoding catenin-binding proteins with function in signalling and/or gene regulation
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767720B1 (en) * 1999-12-23 2004-07-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw CDNAs encoding catenin-binding proteins with function in signalling and/or gene regulation
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAN ET AL.: "a-Catulin knockdown induces senescence in cancer cells.", ONCOGENE, vol. 30, no. 23, 31 January 2011 (2011-01-31), pages 2610 - 21 *
MERDEK ET AL.: "Distinct Activities of the a-Catenin Family, a-Catulin, and a-Catenin, on beta-Catenin-Mediated Signaling.", MOL CELL BIOL., vol. 24, no. 6, March 2004 (2004-03-01), pages 2410 - 2422 *
PARK ET AL.: "Association of Lbc Rho Guanine Nucleotide Exchange Factor with a-Catenin-related Protein, a-Catulin/CTNNAL1, Supports Serum Response Factor Activation.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 47, 20 September 2002 (2002-09-20), pages 45361 - 70 *

Also Published As

Publication number Publication date
WO2013151594A2 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2016001186A (en) Diagnosis and therapy of cancer involving cancer stem cells.
MX2015000428A (en) Compositions and methods for regulating car t cells.
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
WO2014096965A3 (en) Novel heterocyclic compounds as bromodomain inhibitors
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012158780A3 (en) Lung cancer signature
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
WO2014153056A3 (en) Cancer treatment using antibodies that bing cell surface grp78
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
WO2012160333A3 (en) Recombinant yeast expressing human h- ferritin
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
EP3438656A3 (en) Anticancer agent sensitivity-determining marker
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2014151606A3 (en) Methods of treating pancreatic cancer
WO2012151390A3 (en) A therapeutic and diagnostic target gene in acute myeloid leukemia
WO2014052305A3 (en) Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins
MX2015002573A (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell.
WO2011158243A3 (en) Method of diagnosing and treating cancer
WO2011085276A3 (en) Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
WO2014169011A3 (en) Methods for treating immune diseases
WO2014083019A3 (en) Agent for modulating the dissemination of cancer cells, product comprising said agent, and use of said agent in the treatment and/or prevention of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13772662

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13772662

Country of ref document: EP

Kind code of ref document: A2